DATA PAGE

University biotech patenting

Brady Huggett

A list of the most active universities for biotech patents (Table 1) shows the University of California system far ahead of the field. Institut Pasteur is the second most active university for European patents, and Duke ranks second for both US biotech

patents and total patents, ahead of notable institutions such as Stanford, WARF and MIT. Overall, biotech patenting is on the rise, as seen in Figure 1, though the increase is being driven by US patenting.

Table 1 Top universities for biotech patents, 2008–2012

University	Total	Yearly average	US Patent and Trademark Office	European Patent Office
University of California system	721	144.2	591	130
Duke University	303	60.6	277	26
Stanford University	299	59.8	255	44
Wisconsin Alumni Research Foundation (WARF)	281	56.2	240	41
University of Texas system	269	53.8	236	33
Institut Pasteur	244	48.8	136	108
Johns Hopkins University	235	47	184	51
University of Pennsylvania	216	43.2	167	49
University of Michigan	183	36.6	153	30
Massachusetts Institute of Technology (MIT)	159	31.8	140	19
California Institute of Technology	145	29	128	17
New York University	144	28.8	125	19
University of Massachusetts	144	28.8	121	23
Harvard University	142	28.4	109	33
University of Illinois	126	25.2	110	16
University of Washington	120	24	95	25
Yale University	119	23.8	87	32
University of Maryland	118	23.6	104	14
University of Utah	115	23	85	30
University of South Florida	109	21.8	97	12
University of Southern California	99	19.8	75	24
University of North Carolina	98	19.6	72	26
University of Florida	97	19.4	75	22
Rockefeller University	88	17.6	72	16
University of Iowa	88	17.6	75	13
Yissum Hebrew University	83	16.6	47	36
Ramot at Tel Aviv University	56	11.2	34	22
Cornell Research Foundation	52	10.4	43	9
University of Zurich	30	6	21	9

Source: IP Checkups

Figure 1 Biotech patent trends, 2008–2012

Source: IP Checkups

First Rounders Podcast:

William A. Haseltine

Haseltine founded Human Genome Sciences (HGS) in 1992 and ran the firm until 2004, establishing the company at the forefront of applied genomics and producing a new therapy for lupus sufferers. *Nature Biotechnology* spoke to Haseltine about his time at HGS, the future of genomics in drug discovery and how innovation might be funded going forward. <http://www.nature.com/nbt/podcast/index.html>

Brady Huggett is Business Editor at Nature Biotechnology.